SALVADORI, Severo
 Distribuzione geografica
Continente #
NA - Nord America 21.263
AS - Asia 8.616
EU - Europa 5.621
SA - Sud America 1.338
AF - Africa 118
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 10
Totale 36.978
Nazione #
US - Stati Uniti d'America 20.968
SG - Singapore 3.337
CN - Cina 2.698
UA - Ucraina 1.305
DE - Germania 1.274
BR - Brasile 1.129
HK - Hong Kong 905
TR - Turchia 854
GB - Regno Unito 747
IT - Italia 693
FI - Finlandia 460
VN - Vietnam 383
SE - Svezia 347
RU - Federazione Russa 262
FR - Francia 142
MX - Messico 135
CA - Canada 134
PL - Polonia 100
IN - India 86
BE - Belgio 77
AR - Argentina 71
JP - Giappone 64
ZA - Sudafrica 59
BD - Bangladesh 51
ID - Indonesia 50
NL - Olanda 46
ES - Italia 43
CO - Colombia 35
EC - Ecuador 35
LT - Lituania 29
IQ - Iraq 27
AT - Austria 21
IR - Iran 20
CZ - Repubblica Ceca 17
KR - Corea 17
CL - Cile 15
MA - Marocco 15
PK - Pakistan 15
UZ - Uzbekistan 15
PY - Paraguay 14
IL - Israele 13
PE - Perù 13
RO - Romania 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
SA - Arabia Saudita 11
TN - Tunisia 11
EG - Egitto 9
UY - Uruguay 9
CH - Svizzera 8
KE - Kenya 7
NP - Nepal 7
IE - Irlanda 6
JO - Giordania 6
AU - Australia 5
AZ - Azerbaigian 5
BH - Bahrain 5
DO - Repubblica Dominicana 5
EU - Europa 5
LB - Libano 5
NZ - Nuova Zelanda 5
PH - Filippine 5
BG - Bulgaria 4
DZ - Algeria 4
HN - Honduras 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
BO - Bolivia 3
DK - Danimarca 3
GT - Guatemala 3
HR - Croazia 3
KZ - Kazakistan 3
NO - Norvegia 3
PA - Panama 3
SN - Senegal 3
AM - Armenia 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GR - Grecia 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MY - Malesia 2
QA - Qatar 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CV - Capo Verde 1
EE - Estonia 1
GE - Georgia 1
GM - Gambi 1
Totale 36.957
Città #
Fairfield 2.364
Woodbridge 2.349
Singapore 1.880
Ashburn 1.836
Houston 1.584
Jacksonville 1.429
Ann Arbor 1.248
Chandler 1.102
Seattle 911
Beijing 906
Hong Kong 902
Wilmington 847
Santa Clara 834
Cambridge 789
Izmir 437
Nanjing 414
Dallas 343
Munich 310
Princeton 276
Los Angeles 275
San Diego 233
New York 199
Boardman 196
Dearborn 196
Milan 185
Ferrara 151
Ho Chi Minh City 133
Nanchang 121
Falkenstein 117
Helsinki 116
Shenyang 116
São Paulo 111
Hefei 110
Shanghai 101
Mexico City 95
Warsaw 91
Addison 89
Falls Church 81
Hanoi 79
Turku 78
San Mateo 75
Brussels 72
Hebei 72
London 71
Tianjin 67
Auburn Hills 65
Jiaxing 63
Tokyo 63
Bremen 62
Brooklyn 62
Jinan 62
Changsha 61
Chicago 52
Mountain View 49
Buffalo 48
Kunming 47
Moscow 45
San Francisco 42
Redwood City 41
Frankfurt am Main 40
Washington 40
Zhengzhou 39
Philadelphia 38
Toronto 38
Montreal 37
Ningbo 35
Norwalk 35
Johannesburg 34
Orem 34
Poplar 34
Rio de Janeiro 33
The Dalles 33
Stockholm 32
Atlanta 30
Belo Horizonte 30
Denver 29
Boston 28
Columbus 28
Phoenix 28
Guangzhou 27
Bologna 25
Chennai 25
Manchester 24
Tappahannock 24
Des Moines 22
Mcallen 22
Orange 21
Jakarta 20
Charlotte 19
Indiana 19
Biên Hòa 17
Curitiba 17
Haiphong 17
Montréal 17
Augusta 16
Dhaka 16
Ankara 15
Brasília 15
Council Bluffs 15
Mumbai 15
Totale 25.836
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 340
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 285
A cyclic peptide T analogue with high chemotactic activity 257
Design, synthesis and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity 254
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 254
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 246
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 233
A new selective antagonist of the nociceptin receptor 232
A new ligand for the urotensin II receptor 216
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 214
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 209
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 208
Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline‐3‐carboxylic acid at position 2 205
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 204
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 203
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 203
2-Bromoamides as Synthons for Pseudopeptides Containing Aminodicarboxy Units 201
2-Aminoamides and Pseudopeptides Carrying an Amino Group Common to two Residues 201
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 201
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 200
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 199
Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects 199
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 196
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 193
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 189
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 188
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 188
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 187
Dermorphin inhibits spinal nociceptive flexion reflex in humans 187
Physicochemical stability of cabazitaxel and docetaxel solutions 186
Pharmacological characterization of tachykinin tetrabranched derivatives 185
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 184
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 184
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 184
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 184
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 183
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 181
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 180
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 179
Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic 179
Cholinergic mediation in dermorphin-induced growth hormone secretion in man 178
Pharmacological characterization of nociceptin receptor: an in vitro study 176
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 175
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 175
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma 175
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. 174
N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis 173
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 172
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 172
Crystal structures of dipeptides containing the Dmt-Tic pharmacophore 171
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 170
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 169
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 169
Opioid agonists and antagonists. Peptides containing N-terminal allyl groups and/or a thiomethylene linkage in place of a peptide bond 168
Stimulatory effect of dermorphin, a new synthetic potent opiate-like peptide, on human growth hormone secretion 168
Neuropeptide S receptor ligands: a patent review (2005-2016) 168
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 167
Design of d-opioid peptide antagonists for emerging drug applications 167
A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists 166
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 166
Structure-activity study at positions 3 and 4 of human neuropeptide S. 164
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 164
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 163
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 162
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 162
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 161
Responses of plasma renin activity, aldosterone, adrenocorticotropin, and cortisol to dermorphin, a new synthetic potent opiate-like peptide, in man 160
Synthesis and opioid activity of partial retro‐inverso analogs of dermorphin 159
Dermorphin decreases plasma LH levels in human: Evidence for a modulatory role of gonadal steroids 159
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 158
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 157
Prolactin-Releasing Activity of Dermorphin, a New Synthetic Potent Opiate-Like Peptide, in Normal Human Subjects 157
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores 156
Structure–activity relationships of cyclic and linear peptide T analogues 156
Critical role for prokineticin 2 in CNS autoimmunity 156
The nociceptin/orphanin FQ receptor antagonist, [Nphe(1)]NC(1-13)NH2, potentiates morphine analgesia 155
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice 154
The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation 154
Hydrogen sulfide induced disruption of Na+ homeostasis in the cortex 154
Effect of dermorphin on behavior and hippocampal electrical activity in rabbits 153
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 153
Synthetic Approach to non-Isosteric Peptidomimetics Related to Human Endothelin 152
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 152
Assessment of substitution in the second pharmacophore of Dmt-Tic analogues 151
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 150
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 150
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opiold receptor agonist 150
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 150
Characterization of N,N(Me)(2)-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist 149
Somatostatin Inhibits the Dermorphin-Stimulated Thyrotropin Release in Man 149
Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model 149
Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands 148
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 148
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 146
Synthesis and biological activity of carboxyl terminally extended dermorphins 146
Structure-activity relationship study on human urotensin II 146
Opioid receptor selectivity alteration by single residue replacement: Synthesis and activity profile of [Dmt]deltorphin B 145
Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A 145
Synthesis and Pharmacological Activity of Partially Modified Retro-Inverso Dermorphin Tetrapeptides 145
Role of benzimidazole (Bid) in the d-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH2-Bid (UFP-502) 145
Totale 17.853
Categoria #
all - tutte 173.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.952
Totale 175.966


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.028 0 0 0 0 0 366 112 408 84 417 470 171
2021/20222.994 126 290 230 211 230 135 136 170 114 228 224 900
2022/20232.733 297 96 90 335 463 380 148 272 388 16 143 105
2023/20241.291 150 183 94 32 103 233 51 82 17 22 32 292
2024/20255.005 141 106 410 141 637 458 156 346 682 512 749 667
2025/20267.936 1.509 666 1.429 2.046 2.032 254 0 0 0 0 0 0
Totale 37.238